Showing 4961-4970 of 6036 results for "".
- Samsara Vision and Medevise Consulting Announce European Partnershiphttps://modernod.com/news/samsara-vision-and-medevise-consulting-announce-european-partnership/2478956/Samsara Vision announced it will partner with Medevise Consulting to build a dedicated commercial organization to support Samsara Vision’s Tsert SI Implantable Miniature Telescope (IMT) (by Isaac Lipshitz). The two companies will collaborate to advance clinical research, coordinate reimbursement,
- Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trialhttps://modernod.com/news/graybug-vision-reports-preliminary-topline-results-from-phase-2b-altissimo-trial/2478951/Graybug Vision provided preliminary topline data from the 12-month treatment phase of its phase 2b ALTISSIMO trial of GB-102 for the treatment of wet age-related macular degeneration (AMD), Graybug’s proprietary microparticle depot formulation of sunitinib malate injected intravitreally. T
- Over 20,000 Screened for Glaucoma in India and Nigeria Thanks to Joint Initiative, Keep Sighthttps://modernod.com/news/over-20000-screened-for-glaucoma-in-india-and-nigeria-thanks-to-joint-initiative-keep-sight/2478954/Allergan, Sightsavers, and the International Agency for the Prevention of Blindness (IAPB) launched the Keep Sight 2020 video report. The report details the results from the first year of their joint initiative, funded by Allergan, which aims to prevent glaucoma-related vision loss in un
- Allergan Launches Glaucoma in Perspective Apphttps://modernod.com/news/allergan-launches-glaucoma-in-perspective-app/2478950/Allergan has announced the launch of Glaucoma in Perspective (GiP), an app designed to help patients understand the impact of glaucoma, improve quality of life, and reduce disease progression by promoting treatment adherence. The GiP app has been produced and funded by Allergan, with consu
- UK, Four Other Countries to Fast-Track Vaccines for SARS-CoV-2 Variantshttps://modernod.com/news/uk-four-other-countries-to-fast-track-vaccines-for-sars-cov-2-variants/2478939/A group of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland issued new rules Thursday aimed at speeding up the development of modified COVID-19 vaccines against emerging SAR-CoV-2 strains. The guidance, developed by the UK’s Medicines and Healthcare products
- Retina Consultants of America Continues Growth With Partnership in Kansas and Missourihttps://modernod.com/news/retina-consultants-of-america-continues-growth-with-partnership-in-kansas-and-missouri/2478935/Retina Consultants of America (RCA) announced it has added Retina Associates, P.A. of Kansas City, based in Kansas and Missouri, to its group of practices. Retina Associates, P.A. serves the greater Kansas City, Topeka, Sedalia, and surrounding areas. Terms of the deal were no
- Eyenovia Announces FDA Acceptance of Filing of NDA for MydCombihttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-the-mydcombi-nda/2478929/Eyenovia announced that the FDA has accepted the company’s new drug application (NDA) for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent. If approved, MydCombi would be the first microdosed ocular therapeutic applied with a high precision smart delivery system, the Optejet.
- Clearside Biomedical Completes Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-completes-patient-dosing-in-first-cohort-of-phase-1-2a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2478927/Clearside Biomedical announced completion of dosing in the first cohort of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a US-based, multicenter,
- SalioGen Therapeutics Announces Closing of $20 Million Series A Financing to Advance Gene Therapieshttps://modernod.com/news/saliogen-therapeutics-announces-closing-of-20-million-series-a-financing-to-advance-gene-therapies/2478925/SalioGen Therapeutics announced that it has closed a $20 million Series A financing to support the preclinical validation of the company’s proprietary Exact DNA Integration Technology (EDIT) platform for the development of durable, safe and affordable in vivo gene the
- Study: Smartphones Could Help to Prevent Glaucoma Blindnesshttps://modernod.com/news/study-smartphones-could-help-to-prevent-glaucoma-blindness/2478918/Smartphones could be used to scan people’s eyes for early-warning signs of glaucoma, helping to prevent severe ocular diseases and blindness, a new study reveals. Soundwaves used as a mobile measurement method would detect increasing values of IOP, prompting early diagnosis and treatment.</